John W. Smither
Mr. Smither has served on Achaogen’s board of directors since December 2013. Mr. Smither has served as Chief Financial Officer of Sienna Biopharmaceuticals since April 2018. From November 2017 to April 2018, Mr. Smither served as Interim CFO for Kite Pharma, a subsidiary of Gilead Sciences. From January 2016 to July 2017, Mr. Smither served as Chief Financial Officer of Unity Biotechnology. From January 2016 to March 2017, Mr. Smither also served as Chief Financial Officer of Sienna Biopharmaceuticals a biotechnology company. Prior to that, Mr. Smither was the Chief Financial Officer of Kythera Biopharmaceuticals from November 2007 until it was acquired by Allergan in October 2015 for $2.1 billion. As CFO of Kythera, he was responsible for finance during multiple private and public capital raising rounds including the Company’s IPO and subsequent follow-on offerings, licensing and repurchasing of the international rights of its lead product to Bayer, and placement of several venture debt facilities. From 1998 to 2007, Mr. Smither held various positions at Amgen. Including Vice President of Finance and Administration of Amgen’s European Division, Head of Internal Audit, and Executive Director of Corporate Accounting. Prior to joining Amgen, Mr. Smither served as Audit Partner at Ernst & Young LLP, a public accounting firm, and following his time at Ernst & Young had served as the Chief Financial Officer of several early stage companies.
Mr. Smither received a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.